Abstract
Oxaliplatin plays a major role in the treatment of colorectal cancer (crc), but is associated with the development of neuropathies. The main objective of the present prospective study was to estimate the proportion of participants with grade 1, 2, 3, or 4 peripheral sensory neuropathies according to the U.S. National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4) among crc patients treated with oxaliplatin (adjuvant or metastatic, folfox or xelox regimens) at the Centre hospitalier universitaire de Sherbrooke. Among the 57 patients so treated between May 2012 and April 2013, about 60% reported grade 2 neuropathy, at maximum, during treatment. About 25% of patients had to stop treatment because of neuropathies. In a subset of patients contacted approximately 22 months after treatment cessation, neuropathies persisted in 70%. Oxaliplatin-induced neuropathy affects a significant number of crc patients and can influence the course of treatment and outcomes.
Highlights
Colorectal cancer is one of the three most common cancers in North America[1]
The incidence and severity of neuropathy, and its impact on the course of treatment, were unknown in our patient population. We conducted this explorative study to describe the occurrence of peripheral sensory neuropathy in oxaliplatin-treated crc patients at our institution and how it influences the course of treatment
A prospective study conducted at the Centre hospitalier universitaire de Sherbrooke, an academic tertiary care centre in Quebec, included patients who had a diagnosis of crc, were more than 18 years of age, and were newly treated with oxaliplatin regimens such as folfox or xelox or capox in the adjuvant or metastatic setting
Summary
Oxaliplatin is frequently used for crc management in the adjuvant or metastatic setting, and peripheral neuropathy is a dose-limiting effect of that treatment that can persist after cessation of therapy[2]. Previous studies have reported incidences up to 50% for grade 2 or greater neuropathy, and up to 20% for grade 3 or greater neuropathy, but patients with medical conditions or concomitant use of medications that could influence the severity of neuropathy have generally been excluded[3,4,5,6]. The incidence and severity of neuropathy, and its impact on the course of treatment, were unknown in our patient population. We conducted this explorative study to describe the occurrence of peripheral sensory neuropathy in oxaliplatin-treated crc patients at our institution and how it influences the course of treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
